Get the Stockscreener App
1.83
2.23%
0.04
Akebia Therapeutics Inc Stock (AKBA) Forecast
The Akebia Therapeutics Inc (AKBA) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $2.0958, representing a +14.53% increase from the current price of $1.83. The highest analyst price target is $2.6801, and the lowest is $1.5116.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month AKBA Price Target
Average 5.0739
(+177.26% Upside)
Is Akebia Therapeutics Inc (AKBA) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 46.55 | Neutral |
| STOCH(9,6) | 18.09 | Buy |
| STOCHRSI(14) | 26.23 | Neutral |
| MACD(12,26) | -0.00289 | Sell |
| ADX(14) | 22.53 | Neutral |
| William %R | -79.07 | Neutral |
| CCI(14) | -62.26 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.87
Sell
|
1.8611
Sell
|
| MA20 |
1.9475
Sell
|
1.884
Sell
|
| MA50 |
1.7863
Buy
|
1.7903
Buy
|
| MA100 |
1.5764
Buy
|
1.6453
Buy
|
| MA200 |
1.4503
Buy
|
1.499
Buy
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, AKBA could be considered a Potential Buy, with 17 technical analysis indicators signaling 7 Buy signals, 5 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on AKBA, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 46.55 indicates that AKBA is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 18.09 indicates that AKBA is oversold. This indicates that AKBA price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 26.23 indicates that AKBA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 22.53 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -62.26 indicates that AKBA is still oversold but not to an extreme extent.
Long-term AKBA price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Akebia Therapeutics Inc financial reports and earnings history, Akebia Therapeutics Inc (AKBA) stock could reach $4.9522 by 2030, $4.8506 by 2040 and $11.07 by 2050. See the projected annual prices until 2050 of the Akebia Therapeutics Inc stock below:
- Akebia Therapeutics Inc (AKBA) is expected to reach an average price of $1.6814 in 2035, with a high prediction of $1.8837 and a low estimate of $1.709. This indicates an $-8.12% rise from the last recorded price of $1.83.
- Akebia Therapeutics Inc (AKBA) stock is projected to chart a bullish course in 2040, with an average price target of $4.4171, representing an $141.37% surge from its current level. The forecast ranges from a conservative $4.6756 to a sky-high $4.8506.
- Our analysts predict Akebia Therapeutics Inc (AKBA) to jump 363.80% by 2045, soaring from $8.4876 to an average price of $8.4876, potentially reaching $8.5043. While $8.4876 is the low estimate, the potential upside is significant.
- Akebia Therapeutics Inc (AKBA) stock is expected to climb by 2050, reaching an average of $10.59, a $478.86% jump from its current level. However, a wide range of estimates exists, with high and low targets of $11.07 and $10.79, respectively, highlighting the market's uncertainty.
Akebia Therapeutics Inc Stock (AKBA) Year by Year Forecast
Akebia Therapeutics Inc Stock (AKBA) Price Forecast for 2025
Akebia Therapeutics Inc Stock (AKBA) is expected to reach an average price of $5.0739 in 2025, with a high prediction of $9.839 and a low estimate of $0.3088. This indicates an +177.26% rise from the last recorded price of $1.83.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $2.1456 | $1.5116 | $2.6801 | +17.25% |
| February, 2025 | $3.0167 | $2.0284 | $4.524 | +64.85% |
| March, 2025 | $4.3328 | $3.0395 | $6.3601 | +136.77% |
| April, 2025 | $3.4767 | $0.3088 | $5.4806 | +89.99% |
| May, 2025 | $3.4129 | $2.2945 | $3.9229 | +86.50% |
| June, 2025 | $8.434 | $3.5884 | $9.174 | +360.87% |
| July, 2025 | $7.9979 | $6.5851 | $9.0468 | +337.04% |
| August, 2025 | $8.109 | $7.4907 | $9.839 | +343.11% |
| September, 2025 | $7.1601 | $6.9401 | $9.2969 | +291.26% |
| October, 2025 | $1.036 | $1.296 | $7.5928 | -43.39% |
| November, 2025 | $1.185 | $1.1604 | $1.1711 | -35.25% |
| December, 2025 | $1.421 | $0.5365 | $1.1021 | -22.35% |
Akebia Therapeutics Inc Stock (AKBA) Price Forecast for 2026
The predicted value for Akebia Therapeutics Inc (AKBA) in 2026 is set at an average of $0.8571. Estimates vary from a peak of $1.7035 to a trough of $0.0107, indicating an -53.16% surge from the present price of $1.83.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.1999 | $0.7099 | $1.0282 | -89.08% |
| February, 2026 | $0.5337 | $0.4371 | $0.4465 | -70.83% |
| March, 2026 | $0.4376 | $0.5176 | $0.5232 | -76.09% |
| April, 2026 | $1.0163 | $0.2471 | $1.7035 | -44.47% |
| May, 2026 | $0.1374 | $0.0926 | $0.9791 | -92.49% |
| June, 2026 | $0.2615 | $0.0843 | $0.2802 | -85.71% |
| July, 2026 | $0.1924 | $0.2832 | $0.2124 | -89.49% |
| August, 2026 | $0.4635 | $0.0107 | $0.5607 | -74.67% |
| September, 2026 | $0.2674 | $0.0974 | $1.1619 | -85.39% |
| October, 2026 | $0.3515 | $0.0298 | $0.4968 | -80.79% |
| November, 2026 | $0.1003 | $0.2593 | $0.4859 | -94.52% |
| December, 2026 | $0.0965 | $0.1076 | $0.1235 | -94.73% |
Akebia Therapeutics Inc Stock (AKBA) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Akebia Therapeutics Inc (AKBA) is $1.0675, with a high forecast of $2.1053 and a low forecast of $0.0298. This indicates an -41.67% decrease from the last price of $1.83.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $0.00533 | $0.1353 | $0.0847 | -99.71% |
| February, 2027 | $0.0942 | $0.0298 | $0.4502 | -94.85% |
| March, 2027 | $0.3603 | $0.2514 | $0.2303 | -80.31% |
| April, 2027 | $0.5592 | $0.4475 | $0.3942 | -69.44% |
| May, 2027 | $0.8881 | $0.7564 | $0.7309 | -51.47% |
| June, 2027 | $0.2242 | $0.5342 | $0.7874 | -87.75% |
| July, 2027 | $1.8752 | $0.2159 | $0.2986 | +2.47% |
| August, 2027 | $2.0703 | $1.9293 | $2.013 | +13.13% |
| September, 2027 | $2.1053 | $2.1315 | $2.1053 | +15.04% |
| October, 2027 | $2.085 | $2.0765 | $2.0569 | +13.94% |
| November, 2027 | $1.9155 | $1.9983 | $2.0031 | +4.67% |
| December, 2027 | $1.8985 | $1.9318 | $1.9081 | +3.74% |
Akebia Therapeutics Inc Stock (AKBA) Price Forecast for 2028
In 2028, Akebia Therapeutics Inc (AKBA) is projected to reach an average price of $1.2338, with a high projection of $1.8946 and a low estimate of $0.573. This indicates an -32.58% fall from the last price of $1.83.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $1.8808 | $1.9092 | $1.8946 | +2.78% |
| February, 2028 | $1.8935 | $1.883 | $1.8647 | +3.47% |
| March, 2028 | $1.8913 | $1.8958 | $1.8728 | +3.35% |
| April, 2028 | $1.8387 | $1.8447 | $1.8322 | +0.47% |
| May, 2028 | $1.6041 | $1.6658 | $1.8019 | -12.35% |
| June, 2028 | $1.2428 | $1.3076 | $1.4396 | -32.09% |
| July, 2028 | $1.126 | $1.3213 | $1.2791 | -38.47% |
| August, 2028 | $1.0657 | $1.0724 | $1.033 | -41.77% |
| September, 2028 | $1.2735 | $1.2261 | $1.2235 | -30.41% |
| October, 2028 | $0.6724 | $0.9414 | $1.1218 | -63.26% |
| November, 2028 | $0.5985 | $0.6541 | $0.5796 | -67.29% |
| December, 2028 | $0.7324 | $0.573 | $0.6374 | -59.98% |
Akebia Therapeutics Inc Stock (AKBA) Price Forecast for 2029
The 2029 price forecast for Akebia Therapeutics Inc Stock (AKBA) is $1.4981 on average, with a high prediction of $2.955 and a low estimate of $0.0412. This represents an -18.14% decrease from the previous price of $1.83.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.0865 | $0.0635 | $0.5846 | -95.27% |
| February, 2029 | $0.3824 | $0.0707 | $0.2693 | -79.10% |
| March, 2029 | $0.2213 | $0.1968 | $0.164 | -87.91% |
| April, 2029 | $0.5229 | $0.3185 | $0.3402 | -71.43% |
| May, 2029 | $0.4733 | $0.4803 | $0.5241 | -74.14% |
| June, 2029 | $0.2451 | $0.295 | $0.2807 | -86.60% |
| July, 2029 | $0.024 | $0.104 | $0.1304 | -98.69% |
| August, 2029 | $0.4799 | $0.0412 | $0.6199 | -73.78% |
| September, 2029 | $0.201 | $0.171 | $0.5554 | -89.02% |
| October, 2029 | $1.0849 | $0.2338 | $1.1549 | -40.72% |
| November, 2029 | $0.326 | $0.276 | $1.4077 | -82.19% |
| December, 2029 | $3.50 | $0.2216 | $2.955 | +91.26% |
Akebia Therapeutics Inc Stock (AKBA) Price Forecast for 2030
Akebia Therapeutics Inc Stock (AKBA) is expected to reach an average price of $2.6551 in 2030, with a high forecast of $5.1189 and a low forecast of $0.1913. This signifies an +45.09% surge from the last price of $1.83.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $5.2122 | $3.9944 | $4.9522 | +184.82% |
| February, 2030 | $5.01 | $4.8955 | $4.76 | +173.77% |
| March, 2030 | $5.3277 | $5.3633 | $5.1189 | +191.13% |
| April, 2030 | $4.9255 | $4.8166 | $4.7055 | +169.15% |
| May, 2030 | $4.9877 | $4.4988 | $4.7977 | +172.55% |
| June, 2030 | $4.7605 | $4.721 | $4.7922 | +160.14% |
| July, 2030 | $4.4627 | $5.0144 | $4.8744 | +143.86% |
| August, 2030 | $2.3654 | $2.5554 | $2.3569 | +29.26% |
| September, 2030 | $1.4532 | $2.2132 | $1.8743 | -20.59% |
| October, 2030 | $0.4146 | $0.2846 | $1.0446 | -77.35% |
| November, 2030 | $2.5932 | $0.1913 | $2.1951 | +41.70% |
| December, 2030 | $1.5359 | $1.3765 | $1.9376 | -16.07% |
1.61%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):